You are here

  • Home
  • Archive
  • Volume 27, Issue 4
  • Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma

Authors

  • Edwina Coghlan Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; Institute for Health Research, University of Notre Dame Australia, Fremantle; PubMed articlesGoogle scholar articles
  • Tarek M. Meniawy Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; School of Medicine and Pharmacology, University of Western Australia, Crawley; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands; PubMed articlesGoogle scholar articles
  • Aime Munro Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; Institute for Health Research, University of Notre Dame Australia, Fremantle; PubMed articlesGoogle scholar articles
  • Max Bulsara Institute for Health Research, University of Notre Dame Australia, Fremantle; PubMed articlesGoogle scholar articles
  • Colin JR Stewart School of Women’s and Infants’ Health, University of Western Australia, Crawley; Department of Histopathology, King Edward Memorial Hospital, Subiaco; St John of God Pathology, St John of God Subiaco Hospital, Subiaco; PubMed articlesGoogle scholar articles
  • Adeline Tan Department of Histopathology, King Edward Memorial Hospital, Subiaco; St John of God Pathology, St John of God Subiaco Hospital, Subiaco; PubMed articlesGoogle scholar articles
  • MH Eleanor Koay Department of Histopathology, King Edward Memorial Hospital, Subiaco; PubMed articlesGoogle scholar articles
  • Daniel MaGee School of Medicine, University of Notre Dame Australia, Fremantle; PubMed articlesGoogle scholar articles
  • Jim Codde Institute for Health Research, University of Notre Dame Australia, Fremantle; PubMed articlesGoogle scholar articles
  • Jason Tan Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; School of Women’s and Infants’ Health, University of Western Australia, Crawley; School of Medicine, University of Notre Dame Australia, Fremantle; WOMEN Centre, West Leederville; PubMed articlesGoogle scholar articles
  • Stuart G. Salfinger Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; School of Women’s and Infants’ Health, University of Western Australia, Crawley; School of Medicine, University of Notre Dame Australia, Fremantle; PubMed articlesGoogle scholar articles
  • Ganendra R. Mohan Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; School of Women’s and Infants’ Health, University of Western Australia, Crawley; PubMed articlesGoogle scholar articles
  • Yee Leung School of Women’s and Infants’ Health, University of Western Australia, Crawley; PubMed articlesGoogle scholar articles
  • Cassandra B. Nichols Genetics Services of Western Australia, King Edward Memorial Hospital, Subiaco, Western Australia; and Inherited Cancer Connect Partnership, Familial Cancer Centre, Peter MacCallum Cancer Centre, Victoria, Southeast Australia, Australia. PubMed articlesGoogle scholar articles
  • Paul A. Cohen Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; Institute for Health Research, University of Notre Dame Australia, Fremantle; School of Women’s and Infants’ Health, University of Western Australia, Crawley; WOMEN Centre, West Leederville; PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to Paul A. Cohen, FRANZCOG, MD, Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, 12 Salvado Road, Subiaco, Western Australia 6008, Australia. E-mail: paul.cohen{at}sjog.org.au.

Citation

Coghlan E, Meniawy TM, Munro A, et al
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma
International Journal of Gynecologic Cancer 2017;27:708-713.

Publication history

  • Received December 13, 2016
  • Accepted January 13, 2017
  • First published May 1, 2017.
Online issue publication 
January 28, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.